Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $51.43 Million

Wall Street analysts predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will announce $51.43 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings. The highest sales estimate is $53.00 million and the lowest is $49.70 million. Vanda Pharmaceuticals reported sales of $44.28 million in the same quarter last year, which would suggest a positive year over year growth rate of 16.1%. The firm is expected to announce its next earnings report on Wednesday, February 13th.

On average, analysts expect that Vanda Pharmaceuticals will report full-year sales of $191.47 million for the current fiscal year, with estimates ranging from $189.70 million to $193.00 million. For the next year, analysts forecast that the business will post sales of $253.30 million, with estimates ranging from $229.00 million to $292.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The business had revenue of $49.13 million during the quarter, compared to analyst estimates of $49.44 million. During the same quarter in the previous year, the firm earned ($0.03) EPS. Vanda Pharmaceuticals’s revenue was up 18.9% on a year-over-year basis.

A number of equities research analysts have issued reports on VNDA shares. TheStreet upgraded Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, October 26th. Oppenheimer set a $29.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 3rd. Stifel Nicolaus started coverage on Vanda Pharmaceuticals in a research note on Thursday, September 13th. They set a “buy” rating and a $30.00 price target for the company. Citigroup boosted their price target on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, October 16th. Finally, Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research note on Friday, October 12th. Eight research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $35.38.

NASDAQ:VNDA traded up $0.51 during mid-day trading on Monday, reaching $29.45. The company’s stock had a trading volume of 72,922 shares, compared to its average volume of 848,630. Vanda Pharmaceuticals has a 12-month low of $13.30 and a 12-month high of $33.44. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -84.06, a price-to-earnings-growth ratio of 3.94 and a beta of 0.87.

Institutional investors have recently added to or reduced their stakes in the business. United Services Automobile Association bought a new position in shares of Vanda Pharmaceuticals during the 3rd quarter valued at approximately $211,000. Trexquant Investment LP bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at approximately $212,000. Hartford Investment Management Co. bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at approximately $214,000. Meeder Asset Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 164.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 7,102 shares during the period. Finally, NumerixS Investment Technologies Inc grew its stake in shares of Vanda Pharmaceuticals by 92.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 5,700 shares during the period. Institutional investors and hedge funds own 99.33% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: How is the LIBOR rate calculated?

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply